FDA Seeks Clarity On DPP-4 Class Safety Signals With Linagliptin Post-Market Requirements

FDA is using the post-marketing study requirements for Boehringer Ingelheim GmbH's Tradjenta (linagliptin) to investigate some of the emerging safety concerns about the DPP-4 inhibitor class.